Teniposide (VM26) disposition in children with leukemia.

  title={Teniposide (VM26) disposition in children with leukemia.},
  author={Joseph A. Sinkule and Clinton F Stewart and William R. Crom and E T Melton and Gary V H Dahl and William E. Evans},
  journal={Cancer research},
  volume={44 3},
The clinical pharmacokinetics of teniposide (VM-26, NSC 122819) has been studied in 21 children (median age, 4.7 years) with acute lymphocytic leukemia. Teniposide was administered at a dosage of 165 mg/sq m as a 30- to 60-min i.v. infusion. Patients were studied either on the first or second dosage of the drug. Plasma samples were assayed for teniposide and metabolites by high-performance liquid chromatography with electro-chemical detection. Both compartmental and noncompartmental… CONTINUE READING